Ask the Doctor: Dr. Richard Furman on the Latest Treatment Options for CLL/SLL

DRFurman_5284
Dr. Richard Furman, MD

Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are cancers that affect the lymphocytes in the immune system. Essentially the same disease they are differentiated by the location in the body where they occur. CLL is found in the bloodstream, bone marrow, and sometimes the lymph node and spleen of patients, while SLL occurs in the lymph nodes of patients.

On Wednesday, September 21st at 6pm Director of the CLL Research Center, Dr. Richard Furman will give a presentation on currently available treatment options for patients with CLL/SLL. The presentation will be followed by a Q&A session. This presentation is part of the Lymphoma Research Foundation’s (LRF) “Ask the Doctor” program designed specifically for people affected by lymphoma, and seeks to provide the latest information on treatment. Online registration is available here.

The program includes:

  • Overview and Treatment Options for Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma – ( CLL / SLL )
  • Research Updates
  • Question and Answer Session

This program is free-of-charge and dinner will be provided. Pre-registration is required.

Three Easy Ways to Register!

Call: 800-500-9976
Email:  mspellman@lymphoma.org
Web: Click here

Dr. Richard Furman Discusses CLL/SLL Treatments with Lymphoma Research Foundation

Recently, CLL Program Director, Dr. Richard Furman discussed CLL/SLL treatment options with the Lymphoma Research Foundation. On the topic of future treatments Dr. Furman spoke about the exciting treatment options in the future:

“This is a critical time for treatment in CLL because we are witnessing a change in treatment paradigms. We are for the first time seeing the opportunity to move completely away from a dependence on chemotherapy. These new treatments are highly effective and well tolerated. Three new treatments that have recently been approved include ibrutinib, idelalisib and obinutuzumab. There are also two second-generation BTK inhibitors that work similar to ibrutinib and are well tolerated that are in the pipeline,” Dr. Furman said. Regarding the new agents, Dr. Furman makes it clear. “Not only are they preferable because they are better tolerated but because they are also far more effective. Going forward, there is an eye toward not only short term toxicities, but also long- term health. As we continue to identify new agents, the possibility of living a long and full life with minimal toxicity is real for CLL/SLL patients, which is exciting.”

The new treatments for CLL/SLL are currently open in clinical trials. You can follow the link to our clinical trials website to see which trials are available for CLL/SLL.

New Clinical Trial: A Phase 1/2 Proof of Concept Study of the Combination of ACP-196 & ACP-319 in Subjects with B-cell Malignancies

The Weill Cornell Lymphoma Program has recently opened a new clinical trial for men and women with previously treated B-cell malignancies. The study sponsor is Acerta Pharmaceuticals, and the principal investigator at Weill Cornell is Richard Furman M.D.. For more information about the study, please call Amelyn Rodgriguez, RN at (212) 746-1362 or e-mail Amelyn at amr2017@med.cornell.edu.

Key Eligibility

  • Men and women age 18 and older.
  • Diagnosis of non-GCB DLBCL, MCL, FL, WM, or CLL/SLL.
  • At least one prior therapy meeting the criteria for relevant disease type.
  • Detailed eligibility reviewed when you contact the study team.

Study Summary

This clinical trial is for men and women with previously treated B-cell malignancies.

In recent years, clinical trials with small molecule inhibitors of Btk and PI3K-delta have produced high response rates with few drug-related toxicities in subjects with B-cell malignancies. Specifically, ibrutinib and idelalisib have shown very encouraging results and each have gained FDA approval in specific patient populations, however, some subjects develop progressive disease or resistance after a period of time on these treatments. This study aims to assess the clinical potential and safety of a dual inhibition approach by combining ACP-196, a second generation Btk inhibitor, with ACP-319, a second generation PI3K inhibitor. The study will provide more information about whether this targeted combination therapy can benefit subjects with B-cell malignancies over single agent therapies or traditional chemotherapy combinations without an increase in toxicity.

Subjects will receive ACP-196 and ACP-319 continuously throughout the study as long as they are responding to therapy and not experiencing unacceptable side effects. Both ACP-196 and ACP-319 are administered orally twice daily. After discontinuing treatment, subjects will remain in long-term follow-up until they receive their next therapy.